Theravance Biopharma announced a sweeping retrenchment after its Phase 3 trial of ampreloxetine missed the primary endpoint, prompting the company to cease all R&D activity and cut about half its workforce. Management said the decision will enable a narrowed focus on commercial operations tied to existing respiratory products and preserve liquidity while the board examines strategic options including a sale. The company reported the trial miss in symptomatic neurogenic orthostatic hypotension and acknowledged this was the third late‑stage setback for the program. Theravance quantified expected cost savings of roughly $70 million through the third quarter of 2026 and signaled a shift to monetizing existing assets rather than internal discovery. Investors reacted sharply to the readout; the stock plunged and analysts flagged broader implications for small-cap biotechs that concentrate resources on single clinical bets. The rapid wind-down underscores the high binary risk profile of late-stage trials in specialty therapeutics and the financial fragility of single‑asset companies.